CIPLA - IntraDay Trade Analysis with Live Signals

Last Updated Time : 05 Nov 25, 7:43 am

IntraDay Trade Rating: 3.5

📊 Strong fundamentals and valuation support, but weak momentum and declining volume suggest cautious intraday positioning.

📈 Positive

• 💰 Zero debt and strong ROCE (20.1%) and ROE (16.0%) — financially sound.
• 📈 DII holding increased by 1.00% — domestic investor confidence rising.
• 📉 Trading near support zone of ₹1,500 — tactical entry opportunity.
• 📊 P/E of 23.4 vs industry P/E of 33.1 — undervalued relative to peers.

⚠️ Limitation

• 📉 MACD at -4.98 and RSI at 40.1 — weak momentum signals.
• 📉 Volume below average (17.9L vs 25.0L) — reduced intraday interest.
• 📉 Trading below DMA 50 and DMA 200 — short-term trend is weak.

📰 Company Negative News

• 📉 FII holding dropped by 0.70% — foreign investor sentiment softening.
• 📉 PAT declined slightly from ₹1,303 Cr. to ₹1,211 Cr. — marginal earnings contraction.

🌟 Company Positive News

• 📈 EPS of ₹67.3 and PEG ratio of 1.28 — reasonable valuation for growth.
• 📈 Strong brand and consistent performance in the pharmaceutical sector.

💊 Industry

• 💉 Operates in pharmaceuticals — defensive sector with stable demand.
• 📊 Industry P/E of 33.1 — CIPLA trades at a discount, offering value.

📌 Conclusion

• 📉 Moderate intraday potential with valuation support but weak momentum.
• 💡 Optimal buy range: ₹1,495–₹1,500. Target exit: ₹1,520–₹1,530.
• 🛑 Stop-loss: ₹1,485 to manage downside risk.
• 📤 If already holding, consider exiting near ₹1,520 if RSI crosses 45 or MACD flattens intraday.

I can also help you compare CIPLA’s intraday setup with other pharma stocks like Sun Pharma or Dr. Reddy’s for stronger momentum plays.